Citations

Clear

948 citation(s) found for "Li, Bryan".

Cancer treatment–related cognitive impairment
Neth, Bryan J. , Schagen, Sanne B. , Wefel, J. S., Wefel, Jeffrey S. , Wefel, Jeffrey S , Neth, Byran J.

Mayo Clinic

Neuro-Oncology Advances | March 19, 2026 | Volume: 8 | Issue: Supplement_5 | Pages: 37-57

10.1093/noajnl/vdag064 | PMID 42338462 Get It

Abstract There is a growing number of cancer survivors given improvement in early cancer diagnosis, therapeutics, and supportive care strategies. Cognitive impairment is among the most common and clinically significant symptoms managed by cancer survivors, which negatively impacts quality of life, functional and occupational status for patients and their care partners. Cancer-related cognitive impairment is often multifactorial—impacted by patient and cancer-specific factors. For systemic (non-CNS) malignancies, cognitive impairment has been identified in up to 75%, depending on cohort, which persists in up to 35% of patients in the years following initial treatment. The most common areas of impairment include memory and processing speed, and executive function. These adverse effects of cancer treatment have been reported after chemotherapy, hormone therapy, targeted therapy, and immunotherapy. This review will summarize existing knowledge regarding the nature and pattern of cognitive changes, mechanisms and risk factors underlying these changes, and biomarkers to support identification of this adverse consequence of cancer therapies.
Herpesvirus genome integration in whole‐genome sequences of dementia and control cohorts
Piotrowski, Stacey L. , Allnutt, Mary Alice , Johnson, Kory, Ferrucci, Luigi, Morris, Huw, Hardy, John, Ryten, Mina, Logroscino, Giancarlo, Troncoso, Juan C. , Beach, Thomas G., Serrano, Geidy E., Cruchaga, Carlos, Ross, Owen A., Chiò, Adriano, Ding, Jinhui, Scholz, Sonja W. , Jacobson, Steven, Hardy, John , May, Patrick , Scholz, Sonja W , Hardy, John , May, Patrick , Houlden, Henry , Johnson, Kory, Tanaka, Toshiko , Ferrucci, Luigi , Ryten, Mina , Logroscino, Giancarlo , Beach, Thomas G. , Serrano, Geidy E. , Cruchaga, Carlos , Dickson, Dennis W. , Ross, Owen A. , Chiò, Adriano , Houlden, Henry , Dalgard, Clifton L. , Ding, Jinhui , Gibbs, J. Raphael , Traynor, Bryan J. , Jacobson, Steven

Mayo Clinic

Alzheimer's & Dementia | March 19, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71047 | PMID 41853978 Get It

Abstract INTRODUCTION The infectious hypothesis suggests that microbes like herpesviruses may play a role in the pathogenesis of Alzheimer's disease (AD) and other related dementias through methods that may include viral genome integration. The occurrence of herpesvirus genome integration in dementia patients has not been thoroughly characterized. METHODS Over 7500 total whole‐genome sequences from control, frontotemporal dementia/amyotrophic lateral sclerosis spectrum, Lewy body dementia (LBD), multiple system atrophy (MSA), and AD cohorts were screened for the integration of pathogen genomes using the PathSeq computational tool. RESULTS Low PathSeq scores for human herpesvirus 6 (HHV‐6) were consistent with the suspected integration of viral genome segments. The LBD and MSA cohorts had a significantly higher prevalence of this partial HHV‐6 genome integration. DISCUSSION This higher prevalence in both synucleinopathies was not noted in other herpesviruses, suggesting that the integration of HHV‐6 may play a role in a subset of these patients. Highlights Over 7500 whole‐genome sequences from controls and dementia patients were analyzed. Sequences consistent with integrated herpesviruses were identified using PathSeq. Prevalence of partial HHV‐6 integration was higher in synucleinopathies. Herpesviruses genome integration may play a role in subsets of dementia patients.
Woven EndoBridge Device for Ruptured vs. Unruptured Aneurysms: Insights from the WorldWideWEB Study
Dugar, Franja, Essibayi, Muhammed Amir, Adeeb, N, Algin, Oktay, Ghozy, Sherief, Guenego, Adrien, Renieri, Leonardo, Saliou, G, Shotar, Eimad, Möhlenbruch, Markus, Kral, Michael , Chung, Charlotte, Salem, Mohamed M , Cancelliere, Nicole M., Diestro, Jose Danilo Bengzon, Foreman, Paul M. , Shaikh, Hamza, Župančić, Vedran , Waqas, M, Ayberk, Gıyas , Rabinov, James D. , Maingard, Julian , Schirmer, Clemens M., Piano, M, Michelozzi, Caterina , Starke, Robert M., Hassan, A. E., Ogilvie, Mark, Jones, Jesse, Brinjikji, Waleed , Psychogios, Marios, Nawka, Marie Teresa , Fiehler, Jens, Nguyen-Kim, Thi Dan Linh, Pukenas, Bryan , Burkhardt, J. David, Huynh, Thien, Martinez-Gutierrez, Juan Carlos, Sheth, S, Slawski, Diana , Lubicz, Boris , Puri, A, Raz, E, Griessenauer, Christoph J., Asadi, Hamed, Siddiqui, Adnan, Levy, Elad I, Haranhalli, Neil , Altschul, David, Ducruet, Andrew F. , Regenhardt, Robert W., Stapleton, Christopher J. , Kan, Peter , Lylyk, Pedro, Boddu, Srikanth, Knopman, Jared, Tjoumakaris, Stavropoula I., Cuellar-Saenz, Hugo H., Jabbour, Pascal M., Clarençon, Frédéric, Patankar, Tufail , Pereira, Vitor Mendes, Patel, Aman B., Almohammad, Mohammad, Kemmling, Andre, Dmytriw, Adam A., Diestro, Jose Danilo Bengzon , Diestro, Jose Danilo B , Dugar, Franja , Essibayi, Muhammed Amir , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Dibas, Mahmoud , Li, Yan-Lin, Algin, Oktay , Ghozy, Sherief , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo , Carnevale, Joseph, Saliou, Guillaume , Mastorakos, Panagiotis , Shotar, Eimad , Möhlenbruch, Markus , Salem, Mohamed Raafet Ben, Lylyk, Iván , Cancelliere, Nicole M , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Ayberk, Gıyas , Arslan, Muhammet , Ergun, Onur, Maingard, Julian, Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna L., Starke, Robert M., Hassan, Ameer, Ogilvie, Mark , Jones, Jesse , Zaccagna, Fulvio , Grist, James T. , Psychogios, Marios‐Nikos , Fiehler, Jens , Nguyen‐Kim, Thi Dan Linh , Burkhardt, Jan‐Karl , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Tawk, Rabih G. , Pulli, Benjamin , Panni, Pietro , Puri, Ajit S., Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J. , Asadi, Hamed , Siddiqui, Adnan H. , Levy, Elad I. , Altschul, David , Regenhardt, Robert W. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro, Knopman, Jared , Tjoumakaris, Stavropoula , Cuellar, Hugo , Jabbour, Pascal , Clarençon, Frédéric , Limbucci, Nicola , Patel, Aman B. , Almohammad, Mohammad , Kemmling, André , Scarcia, Luca , Dmytriw, Adam A. , Sporns, Peter Bernhard

Mayo Clinic

No container title available | March 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8939206/v1 Get It

Abstract Purpose Although the Woven EndoBridge (WEB) device is increasingly used for the treatment of wide-neck intracranial aneurysms, including in the acute rupture setting, comparative evidence assessing the impact of rupture status remains limited. This study compared angiographic, safety, and clinical outcomes between ruptured and unruptured intracranial aneurysms treated with WEB. Methods We conducted a retrospective analysis of prospectively collected data from the multicenter cohort registry WorldWideWEB, including consecutive adult patients with intracranial aneurysms treated with the WEB. Patients were stratified into groups of ruptured and unruptured aneurysms. Propensity score matching was used to balance baseline characteristics between both groups. Retreatment rate was the primary outcome. Secondary outcomes included mRS, safety events (thromboembolic complications) and angiographic outcomes (periprocedurally and last follow-up). Results Among 1,220 patients, 342 (28.0%) presented with ruptured aneurysms. There was no significant difference in the rate of thromboembolic complications between groups (11.8% vs 5.9%, p = 0.056). At follow-up, adequate occlusion was lower (82.2% vs 93.3%, p < 0.002) and functional outcomes were worse (mRS ≥2 in 34.1% vs 21.9%, p = 0.012) among patients with ruptured aneurysms. Periprocedural adequate occlusion (53.3% vs 53.8%, p>0.9) and retreatment rates (11.8% vs 7.1%, p = 0.14) did not differ between groups after matching. Conclusion Ruptured aneurysms demonstrated expected inferior follow-up functional and angiographic outcomes when compared with unruptured aneurysms, but no difference in retreatment rate and procedural safety. These findings support WEB as a safe and effective treatment option for appropriately selected ruptured intracranial aneurysms in routine clinical practice.
Updated Review: Using the National Cancer Database for Outcomes-Based Research
Ayoade, Oluwaseun, Palis, Bryan E., McCabe, Ryan , Weigel, Ronald J, Canavan, Maureen , Boffa, Daniel J, Caturegli, Giorgio , Weigel, Ronald J. , Boughey, Judy C. , Boffa, Daniel J.

Mayo Clinic

Journal of the American College of Surgeons | March 18, 2026 | Volume: 243 | Issue: 3 | Pages: 696-707

10.1097/xcs.0000000000001924 | PMID 41848188 Get It

BACKGROUND: The National Cancer Database (NCDB) captures 73.7% of newly diagnosed cancers in the USs and underpins thousands of outcomes studies informing oncologic practice. To remain relevant amid rapid therapeutic and policy changes, the NCDB has undergone substantial structural and variable-level revisions. We characterized major updates during the past decade and their implications for research. STUDY DESIGN: We performed a narrative review of annual NCDB data dictionary revisions, American College of Surgeons bulletins, and internal program updates in collaboration with NCDB leadership. Structural modifications, variable additions, and policy changes affecting data capture, follow-up, staging, and accessibility were systematically summarized. RESULTS: The NCDB now includes data from 1,413 Commission on Cancer–accredited hospitals and more than 55 million records. Since 2020, the Rapid Cancer Reporting System enables near–real-time monthly submissions. Embargo periods were reduced from 5 to 3 years for survival data and 2 years for other variables, increasing analytic timeliness. Follow-up was limited to 15 years beginning January 1, 2022. Variable refinements include continuous tumor size in millimeters (since 2016), separation of tumor grade into clinical, pathologic, and posttherapy fields (since 2018), phased radiation treatment reporting (since 2018), and American Joint Committee on Cancer eighth edition staging implementation in January 2018 with nineth edition rollout ongoing. New data elements include Medicaid expansion status (2020), COVID-19 variables (2020 to 2021; 12.4% reduction in cases in 2020), smoking status (2023), and planned programmed death-ligand 1 reporting for non–small cell lung cancer beginning in 2025. CONCLUSIONS: The NCDB has evolved toward more granular, contemporary, and policy-relevant data capture while maintaining broad national coverage. Investigators must account for staging transitions, variable maturation, follow-up limits, and registry-specific biases to ensure valid interpretation of NCDB-based research.
Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)
Al-Samkari, Hanny, Friday, Cassi , Kasthuri, R., Gossage, James R. , Murphy, Charles Griffin, Hountras, Peter, Kirkland, Kristi Jackson, Iyer, Vivek, Prasad, Vikas, Ahluwalia, Vaibhav, Rodriguez-Lopez, Josanna, Conrad, Miles , Hetts, S, Chakinala, Murali M. , Beasley, Melissa, Kirkpatrick, P., Lindquist, Jonathan , Battaile, John T., Lu, An, Parambil, Joseph G. , McCrae, KR, Sheynzon, V., Whitehead, Kevin, Sion, Cassidy, McWilliams, Justin P. , Cusumano, Lucas R. , Trerotola, Scott O. , Chesnutt, Mark S., Kaufman, Claire , Dickey, Melissa Ann, Krock, Nolie, Cottrill, Crystal, Competiello, Tania, Levy, Hara , Clancy, Marianne S. , Henderson, Katharine, Pollak, J., Iyer, Vivek , Al‐Samkari, Hanny , Kasthuri, Raj S. , Al-Samkari, Hanny , Kasthuri, Raj S , Murphy, Charles G , Iyer, Vivek N , Ahluwalia, Vaibhav , Rodriguez-Lopez, Josanna M , Conrad, Miles , Hetts, Steven , Ohliger, Michael , Sisk, Bryan A , Beasley, Melissa A , Lindquist, Jonathan , McCrae, Keith R , Whitehead, Kevin J , Cusumano, Lucas R , Drivas, Theodore G , Kaufman, Claire , Dickey, Melissa , Krock, Nolie , Smith, Karen L. , Kirkland, Kristi, Rodriguez‐Lopez, Josanna , Witkin, Alison S. , Hetts, Steven W. , Sisk, Bryan A. , Lu, An, Whitehead, Kevin J. , Drivas, Theodore G. , Dickey, Melissa , Boyce, Danielle M. , Pollak, Jeffrey

Mayo Clinic

Blood | March 17, 2026 | Volume: 148 | Issue: 4 | Pages: 417-432

10.1182/blood.2026033112 | PMID 41843464 Get It

Abstract Hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vasculopathy affecting 1 in 5000 individuals, is the second most common inherited bleeding disorder worldwide. Despite this prevalence, comprehensive data on disease manifestations and complications remain limited. To address this gap, the US Congress allocated funding leading to the Comprehensive HHT Outcomes Registry of the United States (CHORUS), a prospective, 15-center longitudinal registry enrolling unselected patients with confirmed HHT. In this initial report, we describe findings from the first 600 participants, with a median age of 53 (range, 0-88) years and 60% female. Despite most participants developing typical HHT manifestations by age 13 years, the majority (63%) were not diagnosed until mid-to-late adulthood. Recurrent spontaneous epistaxis occurred in 95% of participants, chronic gastrointestinal bleeding in 30%, and heavy menstrual bleeding in 35% of postmenarche females, together resulting in moderate-to-severe mucosal bleeding in 76%. Iron deficiency and/or anemia were diagnosed in 68%, with 41% requiring IV iron and 25% requiring red cell transfusions. Serious complications of solid-organ arteriovenous malformations were frequent, including intracranial hemorrhage (3%), pulmonary hemorrhage (2%), venous thromboembolism (7%), arterial thromboembolism (11%), heart failure (7%), and pulmonary hypertension (7%). These data from CHORUS, the first national US registry of its kind, provide reliable, real-world estimates of the incidence, prevalence, and severity of numerous HHT manifestations and complications. HHT has a high burden of moderate-to-severe bleeding, anemia, thrombosis, and major neurologic and cardiopulmonary complications. There is a mean interval between first symptoms and diagnosis of &gt;2 decades, during which substantial, serious, and preventable HHT morbidity, including early intracranial hemorrhage, may occur. This trial was registered at clinicaltrials.gov as NCT06259292.
Integrative screening identifies functional variants and VNTRs underlying GWAS signals at the 5p15.33 multi-cancer susceptibility locus
O’Brien, Aidan , Kong, Hyunkyung, Patel, Harsh , Ho, Michelle , Patel, Minal, Zhong, Jun , Xu, Mai, Papenberg, Brenen W. , Connelly, Katelyn E. , Collins, Irene , Hennessey, Rebecca C. , Thakur, Rohit , Sowards, Hayley , Funderburk, Karen, Luong, Thong Minh, Florez-Vargas, Oscar , Myers, Timothy , Jermusyk, Ashley , Gorman, Bryan, Das, Sudipto, (PanScan/PanC4), The Pancreatic Cancer Cohort and Case-Control Consortia, Lan, Qing, Rothman, Nathaniel , McKay, James , Hung, R., Iles, Mark M. , Landi, Maria Teresa , Stolzenberg-Solomon, Rachael Z, Wolpin, Brian M. , Hassan, Manal M. , Antwi, Samuel O. , Lindström, Sara , Stern, Marc-Henri, Andrésson, Þorkell , Shi, Jianxin , Choi, Jiyeon, Brown, Kevin M, Rabe, Kari G. , Patel, Minal B , Hennessey, Rebecca , Luong, Thong , Jones, Kristine , Das, Sudipto , McKay, James , Hung, Rayjean J , Amos, Christopher I , Iles, Mark M , Koutros, Stella , Landi, Maria T , Law, Matthew H , Hassan, Manal M , Klein, Alison P , Orr, Nick , Chanock, Stephen Jacob , Lindstrom, Sara , Hoskins, Jason W , Shi, Jianxin , Prokunina-Olsson, Ludmila , Choi, Jiyeon , Brown, Kevin M , Amundadottir, Laufey , Chaffee, Kari G. , Antwi, Samuel O , Zhong, Jun , Luo, Wen , Lan, Qing , Rothman, Nathaniel , Amos, Christopher I. , Koutros, Stella , Law, Matthew H. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Orr, Nick , Hoskins, Jason W. , Stern, Marc‐Henri , Choi, Jiyeon , Ámundadóttir, Laufey T.

Mayo Clinic

No container title available | March 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.03.26347427 | PMID 41867231 Get It

Abstract Chromosome 5p15.33 harbors several independent association signals which demonstrate antagonistic pleiotropy across cancer types, with causal mechanisms largely unresolved. To identify functional variants and enhancer elements at this locus, we performed statistical fine-mapping followed by massively parallel reporter assays (MPRA) and proliferation based CRISPRi screens. This approach identified eight multi-cancer functional variants (MCFVs) across three GWAS signals. Targeting rs421629 (part of the CLPTM1L signal marked by rs465498) with CRISPRi revealed opposing effects on TERT expression in pancreatic versus lung cancer cells, consistent with the antagonistic pleiotropy observed for this signal. Furthermore, CRISPRi nominated an intronic CLPTM1L variable number tandem repeat (VNTR) as a potent enhancer. Long-read sequencing established VNTR polymorphisms as potential causal variants for the rs465498 signal. We showed that Hippo-pathway transcription factors mediate VNTR enhancer activity in lung and pancreatic cancer cells. Together, these findings indicate that cancer susceptibility at 5p15.33 may be mediated by both SNPs and VNTRs and provide an integrated framework for resolving complex pleiotropic loci.
Streptococcus intermedius Septic Arthritis of the Acromioclavicular Joint with Periarticular Abscesses in an Elderly Man with Diabetes and Recent Canine Exposure: A Case Report and Literature Review
Godart, Gabriel A. , Yadav, Vidit , Wellings, Elizabeth P. , Zummo, Vincent C, Springer, Bryan D. , Durvasula, R, Elwasila, Sammer M., Godart, Gabriel , Stanborough, Rupert O. , Elwasila, Sammer M

Mayo Clinic

Infectious Disease Reports | February 26, 2026 | Volume: 18 | Issue: 2 | Pages: 21

10.3390/idr18020021 | PMID 41874144 Get It

Background/Objectives: Streptococcus intermedius, a member of the Streptococcus anginosus group, is characterized by a marked propensity for abscess formation but only rarely causes native-joint septic arthritis. Involvement of the acromioclavicular (AC) joint is particularly uncommon. We describe a case of native AC joint septic arthritis due to S. intermedius in a patient with multiple predisposing factors and highlight diagnostic and management considerations. Methods: We report the clinical course of a 72-year-old man with poorly controlled type 2 diabetes mellitus who presented with progressive right shoulder pain, erythema, and swelling following recurrent minor skin abrasions from a newly adopted dog. Initial management for presumed inflammatory shoulder pathology included brief systemic corticosteroids and an ultrasound-guided intra-articular ketorolac injection. Magnetic resonance imaging (MRI) was performed after symptom progression. The patient underwent operative irrigation and debridement with collection of synovial fluid and deep tissue cultures. Blood cultures and transthoracic echocardiography were obtained to evaluate for systemic involvement. Results: MRI demonstrated multiloculated periarticular abscesses and osteolysis centered on the AC joint. Operative cultures yielded high colony counts of S. intermedius from synovial fluid and deep tissues. Blood cultures and echocardiography were negative. The patient required multiple operative debridements with irrigation, adjunctive local antibiotic therapy, and prolonged targeted β-lactam treatment. Clinical and radiographic improvement was achieved following surgical source control and antimicrobial therapy. Conclusions: Native AC joint septic arthritis due to S. intermedius is rare. Older age, uncontrolled diabetes, recent intra-articular intervention, and possible zoonotic inoculation from canine wound licking may represent contributory risk factors. Early imaging, prompt surgical source control, and guideline-concordant antimicrobial therapy are essential when bone and soft tissue involvement is present.
Myeloid–Treg Crosstalk Disruption by Photochemical Activation and Immune Checkpoint Therapy Triples Median Survival in a Pancreatic Cancer Model
Hasan, Tayyaba, Saad, Mohammad Ahsan , Allen, Derek , Bergen, Tessa D. van, Morala, Jimena Nicolás , Roberts, Harrison James , Mai, Zhiming , Wang, K. K., Maytin, Edward V. , dong, Haidong, Hasan, Tayyaba , Hasan, Tayyaba , Chandrasekhara, Vinay , Wang, Kenneth K, Spring, Bryan Q. , Dong, Haidong

Mayo Clinic

No container title available | February 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8912367/v1 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to immune checkpoint therapies largely due to immunosuppression mediated by myeloid and lymphoid cells. Effective treatment strategies require, in addition to immune stimulation, the depletion of these immunosuppressive cells and their interactions. Here, we demonstrate for the first time, that a single verteporfin-based photodynamic therapy (PDT) treatment triples median survival in a KPC-PDAC model when combined with anti-PD1 therapy. Mechanistically, apart from reducing CK19 + tumor cells, PDT depletes immunosuppressive myeloid (CD11c+) and lymphoid (FOXP3+) cell populations, by ~ 4- and ~ 18.4-folds, respectively. PDT further disrupts interactions between these immunosuppressive cells, attenuating a key immune-tolerance axis. At the systemic level, PDT reduces splenic immunosuppression through modulation of tumor-derived cytokines. Within this reprogrammed immune-landscape, anti–PD-1 therapy elicits robust CD8 + T-cell responses, reflected by an ~ 6.7-fold increase in the intratumoral CD8+/Treg ratio. Collectively, these findings establish verteporfin-PDT as an immune-priming strategy that complements anti–PD-1 therapy by alleviating immunosuppression in PDAC.
The human insula encodes somatotopic representation of motor execution with an effector-specific connectome map to primary motor cortex
Kerezoudis, P, Jensen, M., Klassen, Bryan T. , Worrell, Greg, Gregg, Nicholas M. , Ince, Nuri F. , Gompel, Jamie J. Van, Hermes, dora, Miller, Kai, Worrell, Gregory A. , Kerezoudis, Panagiotis , Worrell, Gregory A , Gregg, Nicholas M , Kerezoudis, Panagiotis , Jensen, Michael A. , Gompel, Jamie J. Van , Hermes, Dora , Miller, Kai J.

Mayo Clinic

Proceedings of the National Academy of Sciences | February 18, 2026 | Volume: 123 | Issue: 8 | Pages: No page available

10.1073/pnas.2517734123 | PMID 41706878 Get It

Understanding motor representation in the human brain requires mapping beyond the primary motor cortex, into the distributed networks that coordinate complex movements. The insular cortex, a multifunctional hub buried within the Sylvian fissure, has been implicated in motor control through clinical observations and neuroimaging. Yet its precise relation to primary sensorimotor processing remains one of the least understood aspects of motor neurophysiology. To address this gap, we quantified electrophysiological changes from implanted depth electrodes in patients performing simple movement tasks combined with single-pulse electrical stimulation (SPES) to map effective connectivity. The movement data reveal somatotopically specific representation bilaterally, as well as intereffector regions that are active for different movement types. Hand representation is centered along the contralateral ventral aspect of the middle and posterior short gyri bilaterally, while tongue/mouth tuned sites cluster in the dorsal posterior short gyrus and the dorsal long gyri. Insular activity temporally follows the primary motor cortex (M1) and precedes movement onset. SPES revealed somatotopically specific connectivity between corresponding sites in M1 and insula (hand-to-hand, tongue-to-tongue) and between bilateral insulae. These observations establish that somatotopy is a conserved property of distributed motor control incorporating the insular representations and connectivity.
Abstract PS3-01-18: Gene expression signatures of beneficial response to tamoxifen for breast cancer prevention
Winham, S. J., Wang, C., Liu, Y., McCauley, B. M., Tabrizi, D. J., Gehling, D. L., Fischer, J. L., Seymour, L. R., Solanki, M. H., Sherman, M. E., Lohani, K. R., Hoskin, T. L., Radisky, D. C., Degnim, A. C., Winham, S., McCauley, Bryan M. , Gehling, Denice, Seymour, Lisa R. , Sherman, Mark E. , Hoskin, TL, Radisky, Derek C. , Degnim, A.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-01-18-PS3-01-18

10.1158/1557-3265.sabcs25-ps3-01-18 Get It

Abstract Uptake of tamoxifen is limited to 5-15% of all eligible women due to concerns regarding medication side effects combined with the lack of ability to predict which women will benefit from the therapies. We used a unique retrospective sample of n=92 high-risk women with paired benign biopsies obtained before (PreTam) and during tamoxifen (OnTam) to discover tissue gene expression biomarkers of biologic response, defined as change (Δ) in lobular Ki67. Ki67 was digitally quantified in normal lobules from PreTam and OnTam benign tissue samples and samples with PreTam Ki67 = 0 were excluded. Data were analyzed from 51 women with both PreTam and OnTam Ki67 (median age = 49 years and median BMI = 25.5 kg/m2 at PreTam biopsy). OnTam biopsies were collected a median of 11.5 months after PreTam biopsy (median 6.5 months after starting tamoxifen; dose 20 mg/day in 86%). Median Ki67 significantly decreased overall (Δ Ki67 = -0.29%, p=0.003), but the effect was restricted to women with baseline Ki67 ≥ 0.5% (n=38, Δ Ki67 = -0.78%, p=0.0002); no significant change occurred with baseline Ki67 &lt; 0.5 (Δ Ki67 = 0.19%, p=0.23). Δ Ki67 was inversely proportional to baseline Ki67. RNA-seq was successful for 171 benign tissue samples (including 53 PreTam-OnTam pairs). After edgeR normalization (&gt;14,600 genes), PreTam vs OnTam comparison across 33 pairs with baseline Ki67 ≥ 0.5% yielded 66 differentially expressed genes (fold-change &gt; 2 and p&lt;0.01). At p&lt;0.01, ranked gene set enrichment analysis revealed 27 gene sets enriched for reduced expression with Tam (with top-ranked gene set related to steroid hormone biosynthesis) and 59 gene sets enriched for increased expression with Tam (with top-ranking gene sets related to B cell and T cell receptor signaling, regulation of cell cycle, and other immune-related pathways). To identify predictors of response, we correlated baseline PreTam gene expression with Δ Ki67 in 37 women with available baseline PreTam RNAseq and Δ Ki67 data. Partial correlation analysis (via ‘ppcor’ package, adjusted for library qubit) revealed 73 genes with significant positive correlation (rho &gt; 0.50) and 14 genes with significant negative correlation (rho &lt; -0.50) with Δ Ki67 (p&lt;0.01). At p&lt;0.01, ranked gene set enrichment analysis yielded 67 gene sets enriched with negative correlation (i.e. increased expression associated with a reduction in Ki67), including pathways related to ribosome biogenesis, DNA recombination, and nucleic acid metabolic processes; there were 62 gene sets enriched for positive correlation (i.e. decreased expression associated with a reduction in Ki67), including pathways such as VEGF and ERBB signaling. Our data support (i) baseline Ki67 ≥ 0.5 % and (ii) an 87-gene baseline signature as complementary biomarkers of tamoxifen response. Prospective validation of this combined assay could target tamoxifen to the women most likely to benefit, potentially overcoming a major barrier to chemoprevention uptake. Citation Format: S. J. Winham, C. Wang, Y. Liu, B. M. McCauley, D. J. Tabrizi, D. L. Gehling, J. L. Fischer, L. R. Seymour, M. H. Solanki, M. E. Sherman, K. R. Lohani, T. L. Hoskin, D. C. Radisky, A. C. Degnim. Gene expression signatures of beneficial response to tamoxifen for breast cancer prevention [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-01-18.